Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier...
Hence then, the article about adc therapeutics reports second quarter 2026 financial results and provides operational updates was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates )
Also on site :
- This 'Nostalgic' 1980s Calvin Klein Perfume Is Perfect for the Fall-to-Summer Transition and Now 75% Off
- Magnificent Seven Star, With Two Skills Named After Her, Built an Extraordinary Life After Olympic Gold
- Martha Stewart's 'Beautiful' Watercolor Floral Dish Towel Set Brings an 'Elegant Touch' to Any Kitchen